# US 2026/0085286 A1 · Anti-tumor immune response enhancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0085286 A1
- Document ID: US20260085286A1
- Status: Published application
- Kind: A1
- Application number: 19/110,297
- Filed: 2023-08-28
- Published: 2026-03-26
- Earliest claimed: 2022-09-12
- Assignees: Kenichiro HASUMI; National Center for Child Health and Development
- Applicants: National Center for Child Health and Development
- Inventors: Kenichiro HASUMI; Ko RII
- Web page: https://patentgrep.com/patent/US20260085286A1

## CPC

- A61K 31/685: one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
- C12N 5/0639: {Dendritic cells, e.g. Langherhans cells in the epidermis}
- A01K 67/027: New or modified breeds of vertebrates
- A61K 39/39: characterised by the immunostimulating additives, e.g. chemical adjuvants
- A61K 40/19: Dendritic cells
- A61K 40/24: Antigen-presenting cells [APC]
- A61K 40/42: Cancer antigens
- A61P 35/00: Antineoplastic agents
- A61P 37/04: Immunostimulants
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A01K 2207/12: Animals modified by administration of exogenous cells
- A01K 2227/105: Murine
- A01K 2267/0331: Animal model for proliferative diseases
- A61K 2039/585: {wherein the target is cancer}
- A61K 2239/31: characterized by the route of administration
- C12N 2500/36: Lipids
- C12N 2501/999: Small molecules not provided for elsewhere
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A01K: ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention aims to provide means to maintain and enhance the anti-tumor activity of TADC in a tumor microenvironment. The present inventors found that when a composition comprising three kinds of phospholipids “cPLs adjuvant” is administered, the degree of growth of tumors implanted to mice was notably suppressed, and confirmed that immature dendritic cells, when cultured in vitro in the presence of the cPLs adjuvant, become mature bone marrow-derived dendritic cells and induce cytokine production.

## Claims

### Claim 1

An anti-tumor immune response enhancer comprising phosphatidylcholine, phosphatidylethanolamine, and phosphatidylserine.

### Claim 2 (depends on 1)

The anti-tumor immune response enhancer according to claim 1, used for growth suppression of a tumor in a subject.

### Claim 3 (depends on 1)

The anti-tumor immune response enhancer according to claim 1, used for inducing an immature dendritic cell to be a mature dendritic cell.

### Claim 4 (depends on 3)

The anti-tumor immune response enhancer according to claim 3, used for inducing an immature dendritic cell to be CD11b+ CD11c+ viable cells.

### Claim 5 (depends on 4)

The anti-tumor immune response enhancer according to claim 4, wherein the immature dendritic cell is an immature conventional dendritic cell or a tumor-associated dendritic cell.

### Claim 6 (depends on 1)

The anti-tumor immune response enhancer according to claim 1, containing 50 to 90% phosphatidylcholine, 5 to 25% phosphatidylethanolamine, and 5 to 25% phosphatidylserine.

### Claim 7 (depends on 1)

The anti-tumor immune response enhancer according to claim 1, further comprising one or more anticancer agents.

### Claim 8 (depends on 1)

A method for preparing a mature dendritic cell, comprising the step of culturing an immature dendritic cell in vitro in the presence of the anti-tumor immune response enhancer according to claim 1.

### Claim 9 (depends on 2)

The anti-tumor immune response enhancer according to claim 2, containing 50 to 90% phosphatidylcholine, 5 to 25% phosphatidylethanolamine, and 5 to 25% phosphatidylserine.

### Claim 10 (depends on 2)

The anti-tumor immune response enhancer according to claim 2, further comprising one or more anticancer agents.

### Claim 11 (depends on 2)

A method for preparing a mature dendritic cell, comprising the step of culturing an immature dendritic cell in vitro in the presence of the anti-tumor immune response enhancer according to claim 2.
